Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2019

Open Access 01-12-2019 | Ulcerative Colitis | Research

Vitamin D deficiency associated with Crohn’s disease and ulcerative colitis: a meta-analysis of 55 observational studies

Authors: Xi-Xi Li, Yang Liu, Jie Luo, Zhen-Dong Huang, Chao Zhang, Yan Fu

Published in: Journal of Translational Medicine | Issue 1/2019

Login to get access

Abstract

Purpose

To investigate the association of serum levels of 25(OH)D and 1,25(OH)2D3 in healthy and non-healthy controls with Crohn’s disease (CD) and ulcerative colitis (UC).

Methods

Three electronic databases: PubMed, EMbase and EBSCOhost CINAHL, were searched for observational studies to measure the relationship between serum levels of vitamin D (VitD) and CD (or UC).

Results

Fifty-five studies were included in the meta-analysis. We found that mean serum 25(OH)D levels in patients with CD were significantly lower than those in healthy controls (MD: − 3.17 ng/mL; 95% CI − 4.42 to − 1.93). Results from the meta-analysis examining 1,25(OH)2D3 levels in Crohn’s patients revealed higher levels in the CD group than in healthy (MD: 3.47 pg/mL; 95% CI − 7.72 to 14.66) and UC group (MD: 5.05 pg/mL; 95% CI − 2.42 to 12.52). Serum 25(OH)D levels were lower in the UC group than in the healthy control group (MD: − 2.52 ng/mL; 95% CI − 4.02 to − 1.02). In studies investigating the level of 1,25(OH)2D3 in UC and healthy control groups, the level of 1,25(OH)2D3 in the UC groups were found to be higher than that in the control groups (MD: 3.76 pg/mL; 95% CI − 8.36 to 15.57). However, the 1,25(OH)2D3 level in patients with UC was lower than that in CD groups (MD: − 6.71 pg/mL; 95% CI − 15.30 to 1.88). No significant difference was noted between CD patients and UC patients in terms of average serum 25(OH)D levels.

Conclusions

This study found that VitD levels were inversely related to CD and UC. Serum levels of 25(OH)D were lower in patients with CD and UC than in healthy people, and more than half of the patients had insufficient vitamin D levels. The serum level of 1,25(OH)2D3 in both the CD and UC groups was higher than that in healthy people.
Appendix
Available only for authorised users
Literature
1.
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94.PubMedCrossRef
2.
Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53(3):305–53.PubMedPubMedCentralCrossRef
3.
Garg M, Lubel JS, Sparrow MP, Holt SG, Gibson PR. Review article: vitamin D and inflammatory bowel disease—established concepts and future directions. Aliment Pharmacol Ther. 2012;36(4):324–44.PubMedCrossRef
4.
Fiocchi C. Inflammatory bowel disease pathogenesis: where are we? J Gastroenterol Hepatol. 2015;30(Suppl 1):12–8.PubMedCrossRef
5.
Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J, et al. Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol. 2012;12:57.PubMedPubMedCentralCrossRef
6.
Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19(9):1067–77.PubMedCrossRef
7.
Limketkai BN, Mullin GE, Limsui D, Parian AM. Role of vitamin D in inflammatory bowel disease. Nutr Clin Pract. 2017;32(3):337–45.PubMedCrossRef
8.
9.
Gubatan J, Moss AC. Vitamin D in inflammatory bowel disease: more than just a supplement. Curr Opin Gastroenterol. 2018;34(4):217–25.PubMedCrossRef
10.
11.
Barbalho SM, Goulart RA, Gasparini RG. Associations between inflammatory bowel diseases and vitamin D. Crit Rev Food Sci Nutr. 2017;59:1–10.
12.
Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–17.PubMedCrossRef
13.
Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2(7):308–15.PubMedCrossRef
14.
Farraye FA, Nimitphong H, Stucchi A, Dendrinos K, Boulanger AB, Vijjeswarapu A, et al. Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn’s disease. Inflamm Bowel Dis. 2011;17(10):2116–21.PubMedCrossRef
15.
Castro FD, Magalhaes J, Carvalho PB, Moreira MJ, Mota P, Cotter J. Lower levels of vitamin d correlate with clinical disease activity and quality of life in inflammatory bowel disease. Arq Gastroenterol. 2015;52(4):260–5.PubMedCrossRef
16.
Grunbaum A, Holcroft C, Heilpern D, Gladman S, Burstein B, Menard M, et al. Dynamics of vitamin D in patients with mild or inactive inflammatory bowel disease and their families. Nutr J. 2013;12(1):145.PubMedPubMedCentralCrossRef
17.
Ulitsky A, Ananthakrishnan AN, Naik A, Skaros S, Zadvornova Y, Binion DG, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011;35(3):308–16.PubMedCrossRef
18.
Ko KH, Kim YS, Lee BK, Choi JH, Woo YM, Kim JY, et al. Vitamin D deficiency is associated with disease activity in patients with Crohn’s disease. Intest Res. 2018;17(1):70–7.PubMedPubMedCentralCrossRef
19.
Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa scale and the RTI item bank. Clin Epidemiol. 2014;6:359–68.PubMedPubMedCentralCrossRef
20.
Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
21.
22.
Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG. Meta-analysis of continuous outcome data from individual patients. Stat Med. 2001;20(15):2219–41.PubMedCrossRef
23.
24.
Mavridis D, Salanti G. Exploring and accounting for publication bias in mental health: a brief overview of methods. Evid Based Ment Health. 2014;17(1):11–5.PubMedCrossRef
25.
Driscoll RH Jr, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn’s disease. Gastroenterology. 1982;83(6):1252–8.PubMed
26.
Harries AD, Brown R, Heatley RV, Williams LA, Woodhead S, Rhodes J. Vitamin D status in Crohn’s disease: association with nutrition and disease activity. Gut. 1985;26(11):1197–203.PubMedPubMedCentralCrossRef
27.
Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93(9):1483–90.PubMedCrossRef
28.
Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology. 1998;114(5):902–11.PubMedCrossRef
29.
Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis. J Intern Med. 2000;247(1):63–70.PubMedCrossRef
30.
Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol. 2002;37(2):192–9.PubMedCrossRef
31.
Haderslev KV, Jeppesen PB, Sorensen HA, Mortensen PB, Staun M. Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut. 2003;52(5):653–8.PubMedPubMedCentralCrossRef
32.
Tajika M, Matsuura A, Nakamura T, Suzuki T, Sawaki A, Kato T, et al. Risk factors for vitamin D deficiency in patients with Crohn’s disease. J Gastroenterol. 2004;39(6):527–33.PubMedCrossRef
33.
Duggan P, O’Brien M, Kiely M, McCarthy J, Shanahan F, Cashman KD. Vitamin K status in patients with Crohn’s disease and relationship to bone turnover. Am J Gastroenterol. 2004;99(11):2178–85.PubMedCrossRef
34.
Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut. 2004;53(8):1129–36.PubMedPubMedCentralCrossRef
35.
McCarthy D, Duggan P, O’Brien M, Kiely M, McCarthy J, Shanahan F, et al. Seasonality of vitamin D status and bone turnover in patients with Crohn’s disease. Aliment Pharmacol Ther. 2005;21(9):1073–83.PubMedCrossRef
36.
Gilman J, Shanahan F, Cashman KD. Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2006;23(7):1007–16.PubMedCrossRef
37.
Pappa HM, Gordon CM, Saslowsky TM, Zholudev A, Horr B, Shih MC, et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics. 2006;118(5):1950–61.PubMedCrossRef
38.
Sinnott BP, Licata AA. Assessment of bone and mineral metabolism in inflammatory bowel disease: case series and review. Endocr Pract. 2006;12(6):622–9.PubMedCrossRef
39.
Vagianos K, Bector S, McConnell J, Bernstein CN. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2007;31(4):311–9.PubMedCrossRef
40.
Kuwabara A, Tanaka K, Tsugawa N, Nakase H, Tsuji H, Shide K, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int. 2009;20(6):935–42.PubMedCrossRef
41.
Leslie WD, Miller N, Rogala L, Bernstein CN. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol. 2008;103(6):1451–9.PubMedCrossRef
42.
Joseph AJ, George B, Pulimood AB, Seshadri MS, Chacko A. 25(OH) vitamin D level in Crohn’s disease: association with sun exposure & disease activity. Indian J Med Res. 2009;130(2):133–7.PubMed
43.
Kumari M, Khazai NB, Ziegler TR, Nanes MS, Abrams SA, Tangpricha V. Vitamin D-mediated calcium absorption in patients with clinically stable Crohn’s disease: a pilot study. Mol Nutr Food Res. 2010;54(8):1085–91.PubMedPubMedCentral
44.
El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci. 2011;56(3):825–9.PubMedCrossRef
45.
Levin AD, Wadhera V, Leach ST, Woodhead HJ, Lemberg DA, Mendoza-Cruz AC, et al. Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci. 2011;56(3):830–6.PubMedCrossRef
46.
El-Hodhod MA, Hamdy AM, Abbas AA, Moftah SG, Ramadan AA. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC Gastroenterol. 2012;12:44.PubMedPubMedCentralCrossRef
47.
Pappa HM, Langereis EJ, Grand RJ, Gordon CM. Prevalence and risk factors for hypovitaminosis D in young patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;53(4):361–4.PubMedPubMedCentral
48.
Atia A, Murthy R, Bailey BA, Manning T, Garrett LL, Youssef D, et al. Vitamin D status in veterans with inflammatory bowel disease: relationship to health care costs and services. Mil Med. 2011;176(6):711–4.PubMedCrossRef
49.
Suibhne TN, Cox G, Healy M, O’Morain C, O’Sullivan M. Vitamin D deficiency in Crohn’s disease: prevalence, risk factors and supplement use in an outpatient setting. J Crohn’s Colitis. 2012;6(2):182–8.CrossRef
50.
Hassan V, Hassan S, Seyed-Javad P, Ahmad K, Asieh H, Maryam S, et al. Association between serum 25(OH) vitamin D concentrations and inflammatory bowel diseases (IBDs) activity. Med J Malays. 2013;68(1):34–8.
51.
Chatu S, Chhaya V, Holmes R, Neild P, Kang JY, Pollok RC, et al. Factors associated with vitamin D deficiency in a multicultural inflammatory bowel disease cohort. Frontline Gastroenterol. 2013;4(1):51–6.PubMedCrossRef
52.
Fu YT, Chatur N, Cheong-Lee C, Salh B. Hypovitaminosis D in adults with inflammatory bowel disease: potential role of ethnicity. Dig Dis Sci. 2012;57(8):2144–8.PubMedCrossRef
53.
Salacinski AJ, Regueiro MD, Broeder CE, McCrory JL. Decreased neuromuscular function in Crohn’s disease patients is not associated with low serum vitamin D levels. Dig Dis Sci. 2013;58(2):526–33.PubMedCrossRef
54.
Garg M, Rosella O, Lubel JS, Gibson PR. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(12):2634–43.PubMedCrossRef
55.
Prosnitz AR, Leonard MB, Shults J, Zemel BS, Hollis BW, Denson LA, et al. Changes in vitamin D and parathyroid hormone metabolism in incident pediatric Crohn’s disease. Inflamm Bowel Dis. 2013;19(1):45–53.PubMedCrossRef
56.
Miznerova E, Hlavaty T, Koller T, Toth J, Holociova K, Huorka M, et al. The prevalence and risk factors for osteoporosis in patients with inflammatory bowel disease. Bratisl Lek Listy. 2013;114(8):439–45.PubMed
57.
Middleton JP, Bhagavathula AP, Gaye B, Alvarez JA, Huang CS, Sauer CG, et al. Vitamin D status and bone mineral density in African American children with Crohn disease. J Pediatr Gastroenterol Nutr. 2013;57(5):587–93.PubMedCrossRef
58.
Lorinczy K, Lakatos PL, Toth M, Salamon A, Nemes A, Csontos AA, et al. Vitamin D level in Hungarian patients with inflammatory bowel diseases. Orv Hetil. 2013;154(46):1821–8.PubMedCrossRef
59.
Alkhouri RH, Hashmi H, Baker RD, Gelfond D, Baker SS. Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;56(1):89–92.PubMedCrossRef
60.
de Bruyn JR, van Heeckeren R, Ponsioen CY, van den Brink GR, Lowenberg M, Bredenoord AJ, et al. Vitamin D deficiency in Crohn’s disease and healthy controls: a prospective case-control study in the Netherlands. J Crohn’s Colitis. 2014;8(10):1267–73.CrossRef
61.
Dumitrescu G, Mihai C, Dranga M, Prelipcean CC. Serum 25-hydroxyvitamin D concentration and inflammatory bowel disease characteristics in Romania. World J Gastroenterol. 2014;20(9):2392–6.PubMedPubMedCentralCrossRef
62.
Tan B, Li P, Lv H, Li Y, Wang O, Xing XP, et al. Vitamin D levels and bone metabolism in Chinese adult patients with inflammatory bowel disease. J Dig Dis. 2014;15(3):116–23.PubMedCrossRef
63.
Oikonomou KA, Orfanidou TI, Vlychou MK, Kapsoritakis AN, Tsezou A, Malizos KN, et al. Lower fibroblast growth factor 23 levels in young adults with Crohn disease as a possible secondary compensatory effect on the disturbance of bone and mineral metabolism. J Clin Densitom. 2014;17(1):177–84.PubMedCrossRef
64.
65.
Raffner Basson A, Swart R, Jordaan E, Mazinu M, Watermeyer G. Vitamin D deficiency increases the risk for moderate to severe disease activity in Crohn’s disease patients in South Africa, measured by the Harvey Bradshaw index. J Am Coll Nutr. 2016;35(2):163–74.PubMedCrossRef
66.
Thorsen SU, Jakobsen C, Cohen A, Lundqvist M, Thygesen LC, Pipper C, et al. Perinatal vitamin D levels are not associated with later risk of developing pediatric-onset inflammatory bowel disease: a Danish case-cohort study. Scand J Gastroenterol. 2016;51(8):927–33.PubMedCrossRef
67.
Schaffler H, Schmidt M, Huth A, Reiner J, Glass A, Lamprecht G. Clinical factors are associated with vitamin D levels in IBD patients: a retrospective analysis. J Dig Dis. 2018;19(1):24–32.PubMedCrossRef
68.
Opstelten JL, Chan SSM, Hart AR, van Schaik FDM, Siersema PD, Lentjes E, et al. Prediagnostic serum vitamin D levels and the risk of Crohn’s disease and ulcerative colitis in European populations: a nested case–control study. Inflamm Bowel Dis. 2018;24(3):633–40.PubMedCrossRef
69.
Westarp CV, Thomson A, Overton T, Rogers R, Hodges P, Fornasier V, et al. Disorders of mineral and bone metabolism in patients with Crohn’s disease. Can J Gastroenterol Hepatol. 1987;1(1):11–7.
70.
Martin A, Fries W, Luisetto G, Mussolin L, Plebani M, Giacomin D, et al. Bone density and calcium metabolism in patients with long-standing, quiescent Crohn’s disease. Eur J Gastroenterol Hepatol. 1994;6(7):611–6.CrossRef
71.
Souza HN, Lora FL, Kulak CA, Manas NC, Amarante HM, Borba VZ. Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density. Arq Bras Endocrinol Metabol. 2008;52(4):684–91.PubMedCrossRef
72.
Jorgensen SP, Hvas CL, Agnholt J, Christensen LA, Heickendorff L, Dahlerup JF. Active Crohn’s disease is associated with low vitamin D levels. J Crohn’s Colitis. 2013;7(10):e407–13.CrossRef
73.
Burrelli Scotti G, Afferri MT, De Carolis A, Vaiarello V, Fassino V, Ferrone F, et al. Factors affecting vitamin D deficiency in active inflammatory bowel diseases. Dig Liver Dis. 2018;51(5):657–62.PubMedCrossRef
74.
Garg M, Hendy P, Ding JN, Shaw S, Hold G, Hart A. The effect of vitamin D on intestinal inflammation and faecal microbiota in patients with ulcerative colitis. J Crohn’s Colitis. 2018;12(8):963–72.CrossRef
75.
Caviezel D, Maissen S, Niess JH, Kiss C, Hruz P. High prevalence of vitamin D deficiency among patients with inflammatory bowel disease. Inflamm Intest Dis. 2018;2(4):200–10.PubMedPubMedCentralCrossRef
76.
Strisciuglio C, Cenni S, Giugliano FP, Miele E, Cirillo G, Martinelli M, et al. The role of inflammation on vitamin D levels in a cohort of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2018;67(4):501–6.PubMedCrossRef
77.
Garg M, Royce SG, Tikellis C, Shallue C, Sluka P, Wardan H, et al. The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status. Ther Adv Gastroenterol. 2019;12:1756284818822566.CrossRef
78.
Stio M, Retico L, Annese V, Bonanomi AG. Vitamin D regulates the tight-junction protein expression in active ulcerative colitis. Scand J Gastroenterol. 2016;51(10):1193–9.PubMedCrossRef
79.
Kabbani TA, Koutroubakis IE, Schoen RE, Ramos-Rivers C, Shah N, Swoger J, et al. Association of vitamin D level with clinical status in inflammatory bowel disease: a 5-year longitudinal study. Am J Gastroenterol. 2016;111(5):712–9.PubMedCrossRef
80.
Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993;328(24):1747–52.PubMedCrossRef
81.
Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, et al. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol. 2005;97(1–2):179–94.PubMedCrossRef
82.
Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry. 2006;14(12):1032–40.PubMedCrossRef
83.
Hollis BW. Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the clinical environment. Rheum Dis Clin North Am. 2012;38(1):29–44.PubMedCrossRef
84.
85.
DeLuca HF. The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB J. 1988;2(3):224–36.PubMedCrossRef
86.
Guariso G, Gasparetto M, Dalla Pozza LV, D’Inca R, Zancan L, Sturniolo G, et al. Inflammatory bowel disease developing in paediatric and adult age. J Pediatr Gastroenterol Nutr. 2010;51(6):698–707.PubMedCrossRef
87.
Biank V, Broeckel U, Kugathasan S. Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm Bowel Dis. 2007;13(11):1430–8.PubMedCrossRef
88.
Vranesic Bender D, Giljevic Z, Kusec V, Laktasic Zerjavic N, Bosnjak Pasic M, Vrdoljak E, et al. Guidelines for the prevention, detection and therapy of vitamin D deficiency in adults. Lijec Vjesn. 2016;138(5–6):121–32.PubMed
89.
Institute of Medicine Committee to review dietary reference intakes for vitamin D, calcium. The national academies collection: reports funded by National Institutes of Health. In: Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Dietary reference intakes for calcium and vitamin D. Washington (DC): National Academies Press (US) National Academy of Sciences; 2011.
90.
Rockell JE, Skeaff CM, Venn BJ, Williams SM, Green TJ. Vitamin D insufficiency in New Zealanders during the winter is associated with higher parathyroid hormone concentrations: implications for bone health? N Z Med J. 2008;121(1286):75–84.PubMed
91.
Leskovar D, Mestrovic T, Baresic A, Kraljevic I, Panek M, Cipcic Paljetak H, et al. The role of vitamin D in inflammatory bowel disease—assessing therapeutic and preventive potential of supplementation and food fortification. Food Technol Biotechnol. 2018;56(4):455–63.PubMedPubMedCentralCrossRef
92.
Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74(23):1852–9.PubMedPubMedCentralCrossRef
93.
Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses. 1986;21(2):193–200.PubMedCrossRef
94.
Jorgensen SP, Agnholt J, Glerup H, Lyhne S, Villadsen GE, Hvas CL, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease—a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32(3):377–83.PubMedCrossRef
95.
Alrefai D, Jones J, El-Matary W, Whiting SJ, Aljebreen A, Mirhosseini N, et al. The association of vitamin D status with disease activity in a cohort of Crohn’s disease patients in Canada. Nutrients. 2017;9(10):1112.PubMedCentralCrossRef
96.
Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int. 2010;21(7):1121–32.PubMedCrossRef
97.
Leventis P, Kiely PD. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scand J Rheumatol. 2009;38(2):149–53.PubMedCrossRef
98.
Narula N, Cooray M, Anglin R, Muqtadir Z, Narula A, Marshall JK. Impact of high-dose vitamin D3 supplementation in patients with Crohn’s disease in remission: a pilot randomized double-blind controlled study. Dig Dis Sci. 2017;62(2):448–55.PubMedCrossRef
99.
Mathur J, Naing S, Mills P, Limsui D. A randomized clinical trial of vitamin D3 (cholecalciferol) in ulcerative colitis patients with hypovitaminosis D3. PeerJ. 2017;5:e3654.PubMedPubMedCentralCrossRef
100.
Garg M, Rosella O, Rosella G, Wu Y, Lubel JS, Gibson PR. Evaluation of a 12-week targeted vitamin D supplementation regimen in patients with active inflammatory bowel disease. Clin Nutr (Edinburgh, Scotland). 2018;37(4):1375–82.CrossRef
101.
Stepman HC, Vanderroost A, Van Uytfanghe K, Thienpont LM. Candidate reference measurement procedures for serum 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 by using isotope-dilution liquid chromatography-tandem mass spectrometry. Clin Chem. 2011;57(3):441–8.PubMedCrossRef
102.
Tai SS, Bedner M, Phinney KW. Development of a candidate reference measurement procedure for the determination of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal Chem. 2010;82(5):1942–8.PubMedPubMedCentralCrossRef
103.
Wallace AM, Gibson S, de la Hunty A, Lamberg-Allardt C, Ashwell M. Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. Steroids. 2010;75(7):477–88.PubMedCrossRef
104.
Rabenberg M, Scheidt-Nave C, Busch MA, Thamm M, Rieckmann N, Durazo-Arvizu RA, et al. Implications of standardization of serum 25-hydroxyvitamin D data for the evaluation of vitamin D status in Germany, including a temporal analysis. BMC Public Health. 2018;18(1):845.PubMedPubMedCentralCrossRef
105.
Binkley N, Sempos CT. Standardizing vitamin D assays: the way forward. J Bone Miner Res. 2014;29(8):1709–14.PubMedCrossRef
106.
Snellman G, Melhus H, Gedeborg R, Byberg L, Berglund L, Wernroth L, et al. Determining vitamin D status: a comparison between commercially available assays. PLoS ONE. 2010;5(7):e11555.PubMedPubMedCentralCrossRef
107.
Carter GD, Carter R, Jones J, Berry J. How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem. 2004;50(11):2195–7.PubMedCrossRef
108.
Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013;369(21):1991–2000.PubMedPubMedCentralCrossRef
109.
Ananthakrishnan AN, Khalili H, Higuchi LM, Bao Y, Korzenik JR, Giovannucci EL, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology. 2012;142(3):482–9.PubMedCrossRef
Metadata
Title
Vitamin D deficiency associated with Crohn’s disease and ulcerative colitis: a meta-analysis of 55 observational studies
Authors
Xi-Xi Li
Yang Liu
Jie Luo
Zhen-Dong Huang
Chao Zhang
Yan Fu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2019
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-019-2070-5

Other articles of this Issue 1/2019

Journal of Translational Medicine 1/2019 Go to the issue

Research

Overinterpretation of high throughput sequencing data in medical genetics: first evidence against TMPRSS3/GJB2 digenic inheritance of hearing loss

Research

AIBP and APOA-I synergistically inhibit intestinal tumor growth and metastasis by promoting cholesterol efflux

Research

CEBPE expression is an independent prognostic factor for acute myeloid leukemia

Research

Influence of androgenic blockade with flutamide on pain behaviour and expression of the genes that encode the NaV1.7 and NaV1.8 voltage-dependent sodium channels in a rat model of postoperative pain

Research

MicroRNA-regulated pathways of flow-stimulated angiogenesis and vascular remodeling in vivo

Review

In search of an evidence-based strategy for quality assessment of human tissue samples: report of the tissue Biospecimen Research Working Group of the Spanish Biobank Network

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits